The Drug Development RFP from the Alzheimer´s Drug Discovery Foundation provides funding for investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. The grant is available to researchers worldwide, at both non-profit research institutions as well as for-profit organizations. Applicants may apply for up to 5 million USD (direct costs only).
There are three assessment rounds per year and the next letter of intent deadline is May 19, 2023 and full applications are due on July 28, 2023.
